Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 3/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21105969 | 0.96 | GGPS1 (0.50) | GGPS1DNM1S1PR2S1PR1S1PR3 | |
| SCHEMBL19264421 | 0.94 | GGPS1 (0.44) | GGPS1DNM1S1PR2S1PR1S1PR3 | |
| SCHEMBL21418477 | 0.92 | GGPS1 (0.46) | GGPS1DNM1S1PR2S1PR1S1PR3 | |
| SCHEMBL19752131 | 0.91 | GGPS1 (0.40) | GGPS1DNM1PLA2G1BPLA2G2AACE2 | |
| SCHEMBL25015272 | 0.90 | DNM1 (0.56) | GGPS1DNM1S1PR2S1PR1S1PR3 | |
| SCHEMBL25684871 | 0.89 | GGPS1 (0.47) | GGPS1DNM1S1PR2S1PR1S1PR3 | |
| SCHEMBL24849421 | 0.88 | PLA2G1B (0.42) | GGPS1DNM1PLA2G1BPLA2G2AACE2 | |
| SCHEMBL29306455 | 0.88 | LMNA (0.41) | GGPS1DNM1PLA2G1BPLA2G2ALMNA | |
| SCHEMBL13811827 | 0.87 | GGPS1 (0.36) | GGPS1DNM1PLA2G1BPLA2G2AACE2 | |
| SCHEMBL12663272 | 0.85 | PLA2G1B (0.39) | GGPS1DNM1PLA2G1BPLA2G2AACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961180-B2 | Branched trialkyl amine oxides | EASTMAN CHEMICAL COMPANY (US) | 2021-03-30 | — | — | US | disclosed |
| US-10640452-B2 | Branched trialkyl quaternary ammonium compounds | EASTMAN CHEMICAL COMPANY (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190218169-A1 | BRANCHED TRIALKYL AMINE OXIDES | EASTMAN CHEMICAL COMPANY (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190218170-A1 | BRANCHED TRIALKYLAMINE PRECURSORS, INTERMEDIATES, PRODUCTS MADE THEREFROM AND PROCESSES OF MANUFACTURE | EASTMAN CHEMICAL COMPANY (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190218171-A1 | BRANCHED TRIALKYL QUATERNARY AMMONIUM COMPOUNDS | EASTMAN CHEMICAL COMPANY (US) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218169-A1 | BRANCHED TRIALKYL AMINE OXIDES | C5, OR10J3, ALKBH5 | GGPS1 2231/4885DNM1 4865/4885S1PR2 1363/4885 |
| US-20190218171-A1 | BRANCHED TRIALKYL QUATERNARY AMMONIUM COMPOUNDS | ELOVL3, ELOVL5, ALK | GGPS1 2486/4885DNM1 1704/4885S1PR2 1453/4885 |
| US-10640452-B2 | Branched trialkyl quaternary ammonium compounds | BCKDK, PFKL, GLUL | GGPS1 1928/4885DNM1 2807/4885S1PR2 4488/4885 |
| US-20190218170-A1 | BRANCHED TRIALKYLAMINE PRECURSORS, INTERMEDIATES, PRODUCTS MADE THEREFROM AND PROCESSES OF MANUFACTURE | ACADM, ALK, FASN | GGPS1 1291/4885DNM1 4242/4885S1PR2 595/4885 |
| US-10961180-B2 | Branched trialkyl amine oxides | C5, OR10J3, ALKBH5 | GGPS1 2231/4885DNM1 4865/4885S1PR2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.